CIOREVIEW >> Biotech >>

Immune Regulation Announces a Series of Appointments

By CIOReview | Thursday, December 24, 2020
Jonathan M.N. Rigby, CEO

Jonathan M.N. Rigby, CEO

Immune Regulation trumpets a series of appointments to advance its immune resetting therapies for autoimmune and allergic illnesses.

FREMONT, CA: Immune Regulation announces a series of appointments to build out the Board and leadership team that will function alongside Jonathan Rigby, Group CEO of Immune Regulation, in innovating the development of its immune resetting therapies for autoimmune and allergic illnesses. Veteran biotech executive Peter Greenleaf joins Chairman of the Board of Directors. He currently serves as the CEO and member of the Board of Directors of autoimmune therapeutics company Aurinia. He is also a member of the Board of Directors of Antares Pharmaceuticals and Chairman of Biodelivery Sciences International. Jones W. (Woody) Bryan Ph.D., Perry Calias Ph.D., Jeff Myers M.D., Marylyn Rigby, and Nancy Vinh also join Immune Regulations, leadership team.

Woody joins as Chief Business Officer and is a well-regarded business process professional with a very successful healthcare track record. Recently he served as SVP of Business Development at UroGen Pharmaceuticals and as SVP of Business Development at Sucampo Pharmaceuticals. Perry joins as Chief Operating Officer and brings about 25 years of biopharmaceutical experience in clinical development in the drug and device sectors of healthcare. He has an impressive track record in compound development, drug delivery, pipeline progression, and building R&D organizations.

Jeff comes as Chief Medical Officer and is an experienced biotech executive with experience in drug development from pre-clinical to commercial. Jeff served as the SVP of Global Medical Affairs and Interim CMO at Portola Pharmaceuticals through the eventual acquisition by Alexion. While at Gilead, he was the Global Medical Affairs Lead for the CV franchise, including pulmonary hypertension, chronic angina, and cystic fibrosis. Marylyn joins as V.P. of Marketing and Investor Relations and is an experienced pharmaceutical, biotech, and drug delivery professional. She has a successful track record with licensing, B.D., public and private equity financing, strategy, and key corporate functions. Previously she led the marketing and patient outreach programs for a lead development stage product to treat Pulmonary Arterial Hypertension (PAH) at United Therapeutics.

Nancy has been appointed as V.P. Clinical Operations. She has about twenty years of experience managing the early and late phase, international clinical trials for drugs, biologics, cell therapy, and combination products across a wide range of therapeutic areas.